Bevacizumab combined with pegylated liposomal doxombicin and carboplatin in the treatment of recurrent epithelial ovarian cancer
10.7619/jcmp.201413015
- VernacularTitle:贝伐单抗联合脂质体多柔比星和卡铂治疗复发性卵巢上皮性癌的临床研究
- Author:
Yang GU
1
;
Qingqing JIA
Author Information
1. 江苏省苏北人民医院 妇产科
- Keywords:
recurrent epithelial ovarian cancer;
bevacizumab;
pegylated liposomal doxom-bicin;
carboplatin
- From:
Journal of Clinical Medicine in Practice
2014;(13):47-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicity of bevacizumab combined pegy-lated liposomal doxorubicin and carboplatin in the treatment of patients with recurrent epithelial o-varian cancer.Methods Fifty patients with recurrent epithelial ovarian cancer were randomly divid-ed into test group (n =28)and control group (n =22).The patients were received the treatment with bevacizumab combined pegylated liposomal doxorubicin and carboplatin in test group,and were treated with pegylated liposomal doxorubicin and carboplatin chemotherapy in control group.Re-sults In test group,the PFS was 9.1 months,7 patients had CR,13 patients had PR,5 patients had SD,3 patients had PD,the objective response rate was 71.4%.In control group,the PFS was 7.4 months,3 patients had CR,10 patients had PR,3 patients had SD,6 patients had PD,the ob-jective response rate was 59.1%.The total response rate and the PFS in test group were remarkably highly then that in control group.The adverse events related to bevacizumab were hypertension, proteinuria and bleeding.Conclusion It is proved to be effective and safety by bevacizumab com-bined with pegylated liposomal doxombicin and carboplatin in treatment of recurrent epithelial ovari-an cancer patients.
